Sign In
Buy CNTA
$40.50
+0 (+0%)
At Close: Jul 23, 2026
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
07:00am, Tuesday, 13'th Aug 2024
BOSTON and LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transform
Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade
10:56am, Tuesday, 16'th Jul 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 48.9% in Centessa Pharmaceuticals (CNTA). While the effectiveness of this highly sought-after metric is questio
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transfor
Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)
10:36am, Tuesday, 28'th May 2024
Centessa Pharmaceuticals (CNTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ear
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
08:45am, Tuesday, 21'st May 2024
BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines fo
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
04:10pm, Monday, 13'th May 2024
BOSTON and LONDON, May 13, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transforma
Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
02:20pm, Wednesday, 24'th Apr 2024
Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
09:36pm, Tuesday, 23'rd Apr 2024
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are tran
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
04:17pm, Tuesday, 23'rd Apr 2024
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are tran
BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transfor
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
04:28pm, Thursday, 28'th Mar 2024
BOSTON and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial resu
7 Biotech Stocks Ready to Ride the Sector's Resurgence
08:01pm, Monday, 18'th Mar 2024
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
07:00am, Friday, 09'th Feb 2024
BOSTON & LONDON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced that data from an additional 52-weeks of continuous treatment from the third year (Part 5) of t
Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential
01:48pm, Monday, 05'th Feb 2024
Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Monday, 22'nd Jan 2024
BOSTON and LONDON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines f
